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Abstract A cDNA clone encoding angiopoietin-3 protein
(Ang3), a novel member of the angiopoietin family, was
identified. Ang3 cDNA was cloned from a human aorta cDNA
library. Ang3 is a 503 amino acid protein having 45.1% and
44.7% identity with human angiopoietin-1 and human angio-
poietin-2, respectively. Ang3 mRNA is expressed in lung and
cultured human umbilical vein endothelial cells (HUVECs). Ang3
mRNA expression in HUVECs was slightly decreased by
vascular endothelial cell growth factor treatment, suggesting
that the regulation of Ang3 mRNA expression is different from
that of Ang2.
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1. Introduction
Angiogenesis is required for normal embryogenesis, and
also is associated with several pathophysiological conditions
such as the growth of solid tumor [1], neovascularization in
the retina [2], and some in£ammatory diseases [1]. Regulation
of angiogenesis is thought to depend on a balance between
positive and negative regulators [3]. The family of vascular
endothelial growth factors (VEGFs), which are endothelial
cell (EC) speci¢c factors, are known to play a principal role
in angiogenesis, including migration, proliferation [4], and ex-
pression of various genes related to angiogenesis in ECs.
Moreover, the critical role of VEGFs and their receptors in
vascular development of the embryo has been demonstrated
using mutant mice with targeted disruption of VEGFs or the
receptor gene [5^8].
Recently, angiopoietins (angiopoietin-1 (Ang1) and angio-
poietin-2 (Ang2)) were identi¢ed which constitute a novel
family of EC speci¢c factors [9,10]. Ang1 was discovered orig-
inally as a ligand for Tie2, a member of the tyrosine kinase
with immunoglobulin and epidermal growth factor homology
domains receptor (Tie) family [9]. The subsequently cloned
Ang2 also binds Tie2 [10]. Tie2 and the originally cloned iso-
form, Tie1, belong to the Tie receptor family [11^13].
Although both Ang1 and Ang2 have been shown to bind
Tie2 [9,10], no ligand for Tie1 has been identi¢ed. This sug-
gests that the larger number of members constitutes the an-
giopoietin family. Here we report a novel member of the
angiopoietin family, termed angiopoietin-3 (Ang3), which is
expressed in lung as well as in cultured human umbilical vein
endothelial cells (HUVECs).
2. Materials and methods
2.1. The high throughput genomic sequences (htgs) database screening
The htgs database was searched with human angiopoietin amino
acid sequences as probes, using the tblastn program at the National
Center for Biotechnology Information (NCBI, http://www.ncbi.nlm.
znih.gov). One human genomic sequence (GenBank accession number
AC004064) was found to contain eight DNA fragments homologous
to the protein coding region of human Ang1 or Ang2 cDNAs. A part
of these sequences was ampli¢ed by nested polymerase chain reaction
(PCR) using two sets of oligonucleotide primers, designed based on
the putative exons. The sequences of primers were: FW1, 5P-AGC
TAC ACC TTC TTG CTG CC-3P ; FW2, 5P-CCA ACA CCC TCC
AGA GAG AA-3P ; RV1, 5P-G TAT CAT CAT GCG AGA GGC A-
3P ; RV2, 5P-T GCC GTC CAT CTT GTA CTT G-3P. The ¢rst PCR
was performed with a set of FW1 and RV1 and the human aorta
cDNA library (Vgt10, Clontech) as template, followed by the second
PCR with a set of FW2 and RV2. A 1242 bp DNA fragment ampli-
¢ed by the PCR was subcloned into a pGEM-T vector and sequenced.
This DNA fragment was further used for screening a human aorta
cDNA library (Clontech).
2.2. cDNA cloning of human Ang3
To obtain the full-length cDNA, we then screened 1 440 000 plaques
of the human aorta cDNA library under the standard hybridization
conditions, using a 32P-labeled cDNA fragment obtained by nested
PCR as a probe. One clone encoded a partial angiopoietin- like pro-
tein (designated Ang3). This clone contained a poly A tail but lacked
the 5P-terminus of the cDNA. The 5P-terminus of the cDNA was
obtained by the PCR of the human aorta cDNA library. Both strands
of cDNA were sequenced.
2.3. Northern blot analysis
Northern blot analysis was performed under the standard hybrid-
ization conditions with 32P-labeled 1687 bp Ang3 cDNA (nt 235^
1921) as a probe. A membrane (Human Multiple Tissue Northern
Blot; Clontech) containing 2 Wg of poly A RNA in each lane was
hybridized for 16 h, was washed with 0.1USSC (150 mM NaCl, 15
mM sodium citrate, pH 7.0), 0.1% SDS at 50‡C for 1 h, and exposed
to X-ray ¢lm with an intensifying screen at 380‡C for 7 days.
2.4. Analysis of Ang3 expression in HUVECs under VEGF treatment
Con£uent cultures of HUVECs in DMEM containing 1% fetal calf
serum were stimulated with indicated concentrations of human
VEGF. After a 4 h stimulation, total RNA was extracted, and North-
ern blot analysis was performed with 32P-labeled human Ang3 cDNA,
human Ets-1 cDNA, and human glyceraldehyde 3-phosphate dehy-
droxylase (GAPDH) cDNA as probes.
2.5. Radiation hybrid (RH) mapping of the human Ang3 gene
To determine chromosome localization of the Ang3 gene, we per-
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formed RH mapping using the GeneBridge 4 RH panel (Research
Genetics, Huntsville, AL, USA) with two independent sets of primers.
One set is: primer RH upst-1 (5P-GCT CTG AGC AGA CAT CCC
TC-3P), and RH downst-1 (5P-TTC TCT CTG GAG GGT GTT GG-
3P) ; the other is: RH upst-2 (5P-G GAC CCA GAT GCA AGA CAC
T-3P), and RH downst-2 (5P G-GTC TGT TCT CAG CCC ATT C-
3P). The results obtained with these two sets of primers were consis-
tent, and were then sent to the Whitehead Institute/MIT Center for
Genome Research via internet (http://carbon.wi.mit.edu:8000/cgi-bin/
contig/rhmapper.pl) for mapping of the gene relative to the RH map
of the human genome.
3. Results and discussion
By searching the htgs database we found one genomic se-
quence (AC004064) encoding a novel member of the angio-
poietin family, designated Ang3. To ¢nd if the transcript of
the gene encoding Ang3 was present, we attempted to amplify
the cDNA sequence from the human aorta cDNA library
using nested PCR. As we expected, the sequence of the
PCR product (1242 bp) was identical to that of the putative
exons of the Ang3 gene in the database. Accordingly, we
reasoned that there might be a novel member of the angio-
poietin family.
By a combination of the PCR-based method and screening
a human aorta cDNA library, we cloned a full-length cDNA
(1957 bp) encoding Ang3. Ang3 is a 503 amino acid protein
with a signal peptide, predicted by PSORT WWW Server
(http://psort.nibb.ac.jp:8800/). The deduced amino acid se-
quence has 45.1% and 44.7% identity to human Ang1 and
Ang2, respectively (Fig. 1). Ang1 and Ang2 have a character-
istic feature of a coiled-coil domain and ¢brinogen-like do-
main which are conserved in Ang3, further suggesting that
Ang3 constitutes a novel member of angiopoietin family.
Northern blot analysis revealed two Ang3 transcripts of 5.6
kb and 4.0 kb at low levels in lung among the tissues exam-
ined (Fig. 2). Ang3 mRNA is also expressed in HUVECs (Fig.
3). Ang1 is expressed widely in adult tissues, including brain,
skeletal muscles, prostate, ovary, uterus, placenta, and small
intestine [10], while the expression of Ang2 is restricted to
ovary, uterus, placenta, and endothelial cells [10]. Thus, the
tissue distribution of Ang3 di¡ers from those of Ang1 and
Ang2, suggesting that Ang3 might have a role in angiogenesis
distinct from those of Ang1 and Ang2.
Targeted disruption of the gene encoding Ang1 causes se-
vere defects in vascular development; disturbance of angio-
genesis, and lack of mural pericytes in the developing mouse
embryo, leading to death by embryonic day 12.5 [14]. Trans-
genic overexpression of Ang2 disrupts blood vessel formation
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Fig. 1. Comparison of amino acid sequences of human Ang3, Ang1, and Ang2. Amino acids are indicated in single-letter code. Bold letters rep-
resent amino acids identical with Ang3. Dashes indicate gaps. Solid circles denote cysteine residues conserved among Ang3, Ang1, and Ang2.
Coiled-coil domain and ¢brinogen-like domain are boxed.
Fig. 2. Northern blot analysis of Ang3 in human tissues. The sizes
of the transcripts are shown. Each lane contains 2 Wg of poly A
RNA. Skeletal M.: skeletal muscle.
Fig. 3. Changes in Ang3 mRNA expression in HUVEC by VEGF
treatment. After the stimulation with (lanes 2^6) or without (lane 1)
VEGF at various doses, total RNA was isolated and the expression
of Ets-1 (top) and Ang3 (middle) was analyzed by Northern blot-
ting. As loading controls, the signals obtained with a probe for
GAPDH (bottom) are shown. Lane 1: untreated control lanes.
Lanes 2^6: treated with VEGF. The doses used were: 5 ng/ml for
lane 2, 10 ng/ml for lane 3, 20 ng/ml for lane 4, 40 ng/ml for lane
5, 80 ng/ml for lane 6.
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in the mouse embryo similarly to Ang1 knock-out mice [10].
In addition, targeted disruption of the Tie2 gene in mice re-
vealed that angiopoietins and the Tie2 system play critical
roles in embryonic vascular development [15^17]. Angiopoi-
etins also play an considerable role in angiogenesis in adults,
Ang1 inducing the maturation of neovessels while Ang2 elon-
gates them in the presence of VEGF [18]. The e¡ect of Ang3
on angiogenesis remains to be characterized.
Since a recent study has shown that Ang2 mRNA expres-
sion is up-regulated in bovine microvascular endothelial cells
by stimulation of VEGF [19], we then examined the e¡ect of
VEGF on the expression of Ang3 mRNA in HUVECs.
Although mRNA expression levels of Ets-1, a member of
the ets gene family, were increased by VEGF treatment, as
previously reported [20], we found that Ang3 mRNA expres-
sion in HUVECs is instead slightly decreased after the VEGF
treatment (Fig. 3), suggesting that the expression of Ang3 is
regulated by a mechanism di¡erent from that of Ang2.
Targeted disruption of the Tie1 gene, a homolog of Tie2,
indicates that Tie1 is required for the maintenance of vascular
integrity [16]. The ligand of Tie1 is not known at the moment.
In this context, it is important to learn whether Ang3 binds to
either Tie1 or Tie2.
Finally, RH mapping for Ang3 was performed with two
independent primer sets. As shown in Fig. 4, Ang3 was
mapped to the region 0.8 cR telomeric of D20S199
(LODs 3), which locates at chromosome 20p13.
Cloning, tissue expression and chromosomal mapping of a
human angiopoietin-3 protein are required to understand its
role in normal angiogenesis and its pathological states.
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Fig. 4. RH mapping of human Ang3. Distances between STSs are
given in cR3000. Ang3 was mapped to the region 0.8 cR telomeric of
D20S199, which locates at chromosome 20p13.
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